文献速递其他结缔组织病

特发性炎症性肌病治疗的全球差异:一项国际在线调查研究的结果

Global disparities in the treatment of idiopathic inflammatory myopathies: results from an international online survey study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该研究基于COVAD电子调查的横断面辅助分析,纳入来自94个国家的1418例特发性炎症性肌病患者,描述不同大洲、国民总收入(GNI)类别、疾病亚型和器官受累下的治疗分布,并用多因素二元logistic回归分析相关因素。结果显示免疫抑制剂(49.4%)、糖皮质激素(38.5%)、免疫调节剂(13.8%)和IVIG(9.4%)的使用存在明显地区差异,多数差异在多因素分析后仍持续存在。作者认为需要制定兼顾以患者为中心的照护和可用资源的国际共识管理指南。

要点

  • 纳入1418例特发性炎症性肌病患者,免疫抑制剂使用49.4%、糖皮质激素38.5%、免疫调节剂13.8%、IVIG 9.4%。
  • 治疗在不同地区、GNI类别、疾病亚型和表现间存在差异,免疫抑制剂多用于中高收入国家,IVIG和生物制剂主要限于高收入国家。
  • 多数地区间治疗差异在多因素分析后仍持续存在。

核心结论

  • 研究在特发性炎症性肌病全球队列中发现了明显的地区治疗差异。
  • 作者认为这些观察结果凸显了制定国际共识驱动的管理指南的必要性,指南应兼顾以患者为中心的照护和可用资源。

研究设计与样本

  • 对「自身免疫病中的COVID-19疫苗接种」(COVAD)电子调查进行横断面辅助分析,收集人口学特征、特发性炎症性肌病亚型、当前症状和治疗信息。
  • 共分析来自94个国家的1418例特发性炎症性肌病受访者,年龄61岁,女性占62.5%。
  • 治疗按大洲、GNI、特发性炎症性肌病亚型和器官受累进行描述性呈现,相关因素采用多因素二元logistic回归分析。

主要发现

  • 最常见的亚型为皮肌炎(32.4%)、包涵体肌炎(24.5%)和重叠肌病(15.8%)。
  • 治疗类别包括免疫抑制剂(49.4%)、糖皮质激素(38.5%)、免疫调节剂(13.8%)和IVIG(9.4%)。
  • 免疫抑制剂多用于中高收入国家,免疫调节剂多用于中低收入国家,IVIG和生物制剂主要限于高收入国家。
  • 免疫抑制剂和糖皮质激素与抗合成酶综合征相关,免疫调节剂与重叠肌病和皮肌炎相关,IVIG与免疫介导坏死性肌病相关,生物制剂与重叠肌病和抗合成酶综合征相关。
  • 免疫抑制剂和糖皮质激素与呼吸困难相关;多数地区间治疗差异在多因素分析后仍持续存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to explore current practice and interregional differences in the treatment of idiopathic inflammatory myopathies (IIMs). We triangulated these observations considering countries' gross national income (GNI), disease subtypes, and symptoms using patient-reported information. METHODS: A cross-sectional ancillary analysis of the 'COVID-19 vaccination in auto-immune disease' (COVAD) e-survey containing demographic characteristics, IIM subtypes (DM, PM, IBM, anti-synthetase syndrome [ASSD], immune-mediated necrotizing myopathy [IMNM], overlap myopathies [OM]), current symptoms (surrogate for organ involvement) and treatments (corticosteroids [CS], immunomodulators [IM], i.e. antimalarials, immunosuppressants [IS], IVIG, biologic treatments and targeted-synthetic small molecules). Treatments were presented descriptively according to continents, GNI, IIM and organ involvement, and associated factors were analysed using multivariable binary logistic regressions. RESULTS: Of 18 851 respondents from 94 countries, 1418 with IIM were analysed (age 61 years, 62.5% females). DM (32.4%), IBM (24.5%) and OM (15.8%) were the most common subtypes. Treatment categories included IS (49.4%), CS (38.5%), IM (13.8%) and IVIG (9.4%). Notably, treatments varied across regions, GNI categories (IS mostly used in higher-middle income, IM in lower-middle income, IVIG and biologics largely limited to high-income countries), IIM subtypes (IS and CS associated with ASSD, IM with OM and DM, IVIG with IMNM, and biologic treatments with OM and ASSD) and disease manifestations (IS and CS with dyspnoea). Most inter-regional treatment disparities persisted after multivariable analysis. CONCLUSION: We identified marked regional treatment disparities in a global cohort of IIM. These observations highlight the need for international consensus-driven management guidelines considering patient-centred care and available resources.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ziade N, Aoude M, Hmamouchi I, et al. Global disparities in the treatment of idiopathic inflammatory myopathies: results from an international online survey study. Rheumatology (Oxford). 2024. PMID: 37228012. doi:10.1093/rheumatology/kead250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。